CD314 (NKG2D), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-CD314 (NKG2D), Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CD314 (NKG2D), Human |
| Clone | REA1228 |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | IgG1 |
| Format | PE-Vio 615 conjugate |
| Size | 30 tests in 60 µL |
| Concentration | 1:50 |
| Applications | Flow cytometry |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | CD314 (NKG2D) Antibody, anti-human, PE-Vio® 615, REAfinity™. Clone REA1228 recognizes CD314 (NKG2D), a cell surface receptor of the type II transmembrane receptor NKG2 family. It is expressed on natural killer (NK) cells, CD8+ α/β T cells, and γ/δ T cells. Though NKG2D itself possesses no intrinsic signaling capability, ligand engagement while associated to the adaptor proteins DAP10 or DAP12 induces cytolytic activation in NK cells as well as costimulation in certain T cell populations. Ligands for NKG2D are stress-inducible MHC Class I-related MICA, MICB, and UL16-binding proteins, expressed predominantly on epithelial cells and numerous carcinomas. | Additional information: Clone REA1228 displays negligible binding to Fc receptors. |
| Immunogen | n/a |
| Other Names | Klrk1, KLR, NKG2D |
| Gene, Accession # | Gene ID: 22914 |
| Catalog # | 130-124-352 |
| Price | $154 |
| Order / More Info | CD314 (NKG2D), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Maasho, K. et al. (2005) NKG2D is a costimulatory receptor for human naive CD8+ T cells. J Immunol 174: 4480-4484. | Bauer, S. et al. (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285: 727-729. | Groh, V. et al. (2003) Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc. Natl. Acad. Sci. U.S.A. 100 (16): 9452-9457. | Moretta, L. and Moretta, A. (2004) Unravelling natural killer function: Triggering and inhibitory human NK receptors. EMBO J. 23: 255-259. | Warren, H. S. (2005) The Eighth Human Leucocyte Differentiation Antigen (HLDA8) Workshop: Natural killer cell section report. Cell. Immunol. 236: 17-20. | Chaput, N. et al. (2013) Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR+ NK cell levels correlate with disease outcome. Oncoimmunology 2 (2): e23080. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies